Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Renin-angiotensin System Inhibitors and Development of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Author(s): Fereshteh Asgharzadeh, Reza Jafarzadeh-Esfehani, Seyed M. Hassanian, Gordon A. Ferns, Amir Avan* and Majid Khazaei*

Volume 26, Issue 39, 2020

Page: [5079 - 5085] Pages: 7

DOI: 10.2174/1381612826666200713165018

Price: $65

Abstract

Background: There are controversial results available about using angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) and the development of cancers or improvement of clinical outcomes. Studies reported that using ACEI/ARB may enhance the development of hepatocellular carcinoma (HCC) and clinical outcomes.

Objective: This meta-analysis aimed to assess the relationship between ACEI/ARB therapy and the development of HCC.

Methods: PubMed, EMBASE and the Cochrane library were reviewed to identify clinical studies investigating the association between ACEI/ARB therapy and the risk of HCC development. The pooled risk ratio (RR) with 95% confidence intervals collected for the association between using ACEIs/ARBs and HCC development.

Results: Patients with HCC benefit from the treatment with both ACEIs and ARBs (RR 0.704, 95% CI 0.526- 0.944, p = 0.019). However, only using ARBs was related to HCC risk (0.545 95% CI 0.470-0.632, P<0.0001). Moreover, the study types were significantly related to the observed effects of using both ARBs and ACEIs. Only cohort studies were significantly related to achieving better results (RR=0.513, 95% CI= 0.442-0.597, P<0.0001).

Conclusion: Despite the small number and heterogeneity of the studies evaluating the relationship between treatment with ARBs and ACEIs and the development of HCC, our meta-analysis demonstrates that they may reduce the risk of HCC.

Keywords: Angiotensin receptor blocker, angiotensin-converting enzyme inhibitor, hepatocellular carcinoma, therapy, heterogeneity, cohort studies.

« Previous
[1]
Li S, Li T, Li X, et al. MicroRNA-32 regulates development and progression of hepatocellular carcinoma by targeting ADAMTS9 and affects its prognosis. Med Sci Monit Basic Res 2018; 24: 177-87.
[http://dx.doi.org/10.12659/MSMBR.910522] [PMID: 30393368]
[2]
Sayiner M, Golabi P, Younossi ZM. Disease burden of hepatocellular carcinoma: A global perspective. Dig Dis Sci 2019; 64(4): 910-7.
[http://dx.doi.org/10.1007/s10620-019-05537-2] [PMID: 30835028]
[3]
Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: Consider the population. J Clin Gastroenterol 2013; 47 Suppl(0): S2-6.
[http://dx.doi.org/10.1097/MCG.0b013e3182872f29] [PMID: 23632345]
[4]
Halegoua-De Marzio D, Hann HW. Prevention of hepatocellular carcinoma and its recurrence with anti-hepatitis B viral therapy. Minerva Gastroenterol Dietol 2014; 60(3): 191-200.
[PMID: 25000955]
[5]
Tao J, Liu Z, Wang Y, et al. MicroRNA-645 represses hepatocellular carcinoma progression by inhibiting SOX30-mediated p53 transcriptional activation. Int J Biol Macromol 2019; 121: 214-22.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.10.032] [PMID: 30312695]
[6]
Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019; 156(2): 447-91.e1.
[PMID: 30367835]
[7]
Wang F, Dai M, Chen H, et al. Prognostic value of hsa-mir-299 and hsa-mir-7706 in hepatocellular carcinoma. Oncol Lett 2018; 16(1): 815-20.
[http://dx.doi.org/10.3892/ol.2018.8710] [PMID: 29963149]
[8]
Tchaikovski V, Lip GY. Angiotensin receptor blockers and tumorigenesis: Something to be (or not to be) concerned about? Curr Hypertens Rep 2012; 14(3): 183-92.
[http://dx.doi.org/10.1007/s11906-012-0263-x] [PMID: 22467342]
[9]
Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22(5): 820-8.
[http://dx.doi.org/10.1200/JCO.2004.06.022] [PMID: 14990637]
[10]
Jafarzadeh Esfehani R, Mahmoodi Gharai A, Jafarzadeh Esfehani A, Rezaie Kalat A, Abbasi F, Jalalyazdi M. A comparative study of the management of stage 2 hypertension by combined therapy with losartan, amlodipine and hydrochlorothiazide. Int Cardiovasc Res J 2012; 6(3): 79-83.
[PMID: 24757597]
[11]
Misra S, Stevermer JJ. ACE inhibitors and ARBs: One or the other-not both-for high-risk patients. J Fam Pract 2009; 58(1): 24-7.
[PMID: 19141267]
[12]
Singh KD, Karnik SS. Angiotensin receptors: Structure, function, signaling and clinical applications. J Cell Signal 2016; 1(2): 8.
[PMID: 27512731]
[13]
Alvarenga EC, Fonseca MC, Carvalho CC, et al. Angiotensin converting enzyme regulates cell proliferation and migration. PLoS One 2016; 11(12)e0165371
[http://dx.doi.org/10.1371/journal.pone.0165371] [PMID: 27992423]
[14]
Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352(9123): 179-84.
[http://dx.doi.org/10.1016/S0140-6736(98)03228-0] [PMID: 9683206]
[15]
Mc Menamin ÚC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: A systematic review. Cancer Causes Control 2012; 23(2): 221-30.
[http://dx.doi.org/10.1007/s10552-011-9881-x] [PMID: 22116540]
[16]
Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007; 22(4): 577-84.
[http://dx.doi.org/10.1111/j.1440-1746.2006.04797.x] [PMID: 17376054]
[17]
Uemura H, Ishiguro H, Nakaigawa N, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003; 2(11): 1139-47.
[PMID: 14617787]
[18]
Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis: A computer program for research synthesis (Vers 22). Englewood, NJ: Biostat. Inc 2005.
[19]
de Groot C. Vitamin B 12, folate, homocysteine, and bone health in adults and elderly people: A systematic review with meta-analyses. J Nut Metabol 2013.
[20]
Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular carcinoma: Risk factors, diagnosis and treatment. Open Access Maced J Med Sci 2015; 3(4): 732-6.
[http://dx.doi.org/10.3889/oamjms.2015.111] [PMID: 27275318]
[21]
Ghandehari M, Dehnavi Z, Razmpour F, et al. Associations of anthropometric parameters and hepatic steatosis. J Nut Fasting Health 2020; 8(1): 23-7.
[22]
Ghandehari M, Soleimani D, Sedaghat M, et al. Comparison of diet records between patients with non-alcoholic fatty liver disease and controls. J Nut Fasting Health 2019; 7(3): 146-50.
[23]
Parizadeh SM, Parizadeh SA, Alizade-Noghani M, et al. Association between non-alcoholic fatty liver disease and colorectal cancer. Expert Rev Gastroenterol Hepatol 2019; 13(7): 633-41.
[http://dx.doi.org/10.1080/17474124.2019.1617696]
[24]
Parizadeh SM, Jafarzadeh-Esfehani R, Ghandehari M, et al. MicroRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Curr Drug Targets 2019; 20(11): 1129-40.
[http://dx.doi.org/10.2174/1389450120666190307095720]
[25]
Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(15): 4115-27.
[http://dx.doi.org/10.3748/wjg.v20.i15.4115] [PMID: 24764650]
[26]
Rahmani F, Ziaeemehr A, Shahidsales S, et al. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma. J Cell Physiol 2019.
[27]
Walker AJ, West J, Grainge MJ, Card TR. Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database. Cancer Causes Control 2011; 22(12): 1743-7.
[http://dx.doi.org/10.1007/s10552-011-9837-1] [PMID: 21909951]
[28]
Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002; 294(2): 441-7.
[http://dx.doi.org/10.1016/S0006-291X(02)00496-5] [PMID: 12051731]
[29]
Khakoo AY, Sidman RL, Pasqualini R, Arap W. Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 2008; 68(22): 9112-5.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-0851] [PMID: 19010879]
[30]
Barone M, Viggiani MT, Losurdo G, Principi M, Leo AD. Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2524-38.
[http://dx.doi.org/10.3748/wjg.v25.i20.2524] [PMID: 31171895]
[31]
Yoshiji H, Noguchi R, Ikenaka Y, et al. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep 2011; 26(6): 1547-53.
[http://dx.doi.org/10.3892/or.2011.1433] [PMID: 21874260]
[32]
Yoshiji H, Noguchi R, Namisaki T, et al. Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance. Oncol Rep 2013; 30(2): 545-52.
[http://dx.doi.org/10.3892/or.2013.2497] [PMID: 23708326]
[33]
Sugiura R, Ogawa H, Oka T, Koyanagi R, Hagiwara N. HIJ-CREATE Investigators. Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). Am J Cardiol 2012; 109(4): 576-80.
[http://dx.doi.org/10.1016/j.amjcard.2011.09.050] [PMID: 22100194]
[34]
Chang CH, Lin JW, Wu LC, Lai MS. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 2011; 29(22): 3001-7.
[http://dx.doi.org/10.1200/JCO.2011.35.1908] [PMID: 21690476]
[35]
Wang KL, Liu CJ, Chao TF, et al. Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis. Int J Cardiol 2013; 167(5): 2162-6.
[http://dx.doi.org/10.1016/j.ijcard.2012.05.096] [PMID: 22709730]
[36]
Lindholm LH, Anderson H, Ekbom T, et al. Relation between drug treatment and cancer in hypertensives in the swedish trial in old patients with hypertension 2: A 5-year, prospective, randomised, controlled trial. Lancet 2001; 358(9281): 539-44.
[http://dx.doi.org/10.1016/S0140-6736(01)05704-X] [PMID: 11520524]
[37]
Facciorusso A, Del Prete V, Crucinio N, et al. Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. J Gastroenterol Hepatol 2015; 30(11): 1643-50.
[http://dx.doi.org/10.1111/jgh.12988] [PMID: 25974743]

Rights & Permissions Print Cite
Article Metrics
13
© 2024 Bentham Science Publishers | Privacy Policy